Reference entry
Chonluten (EDG)
EDG Tripeptide · Bronchial/Lung Bioregulator
Overview
Chonluten is a Khavinson bioregulator tripeptide (EDG) derived from respiratory lung tissue. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it targets the bronchopulmonary system with secondary activity in the GI tract. Research shows it regulates genes related to inflammation, antioxidant activity, and proliferation responses. Chonluten inhibits TNF production in monocytes and has been studied as a potential geroprotective agent that may support lung function in conditions like COPD.
Chonluten works through epigenetic regulation, penetrating cell and nuclear membranes to bind promoter or suppressor regions of DNA and modulate transcriptional control. It regulates genes including c-Fos, HSP70 (heat-shock protein), SOD (superoxide dismutase), COX-2, and TNF-alpha related to oxidative stress and proliferative regulation. The peptide inhibits TNF production in monocytes exposed to pro-inflammatory LPS, promoting attenuation of inflammatory action through TNF tolerance mechanisms.
Normalizes respiratory system function through gene expression regulation.
Restores and maintains lung alveolar tissues and bronchial mucous membranes.
May modulate mucosal function in chronic obstructive pulmonary disease.
Inhibits TNF production in monocytes, reducing inflammatory responses.
Mechanism
Chonluten is a Khavinson bioregulator tripeptide (EDG) derived from respiratory lung tissue. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it targets the bronchopulmonary system with secondary activity in the GI tract. Research shows it regulates genes related to inflammation, antioxidant activity, and proliferation responses. Chonluten inhibits TNF production in monocytes and has been studied as a potential geroprotective agent that may support lung function in conditions like COPD.
Chonluten works through epigenetic regulation, penetrating cell and nuclear membranes to bind promoter or suppressor regions of DNA and modulate transcriptional control. It regulates genes including c-Fos, HSP70 (heat-shock protein), SOD (superoxide dismutase), COX-2, and TNF-alpha related to oxidative stress and proliferative regulation. The peptide inhibits TNF production in monocytes exposed to pro-inflammatory LPS, promoting attenuation of inflammatory action through TNF tolerance mechanisms.
Normalizes respiratory system function through gene expression regulation.
Research areas
- Chonluten is a Khavinson bioregulator tripeptide (EDG) derived from respiratory lung tissue. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it targets the bronchopulmonary system with secondary activity in the GI tract. Research shows it regulates genes related to inflammation, antioxidant activity, and proliferation responses. Chonluten inhibits TNF production in monocytes and has been studied as a potential geroprotective agent that may support lung function in conditions like COPD.
- Chonluten works through epigenetic regulation, penetrating cell and nuclear membranes to bind promoter or suppressor regions of DNA and modulate transcriptional control. It regulates genes including c-Fos, HSP70 (heat-shock protein), SOD (superoxide dismutase), COX-2, and TNF-alpha related to oxidative stress and proliferative regulation. The peptide inhibits TNF production in monocytes exposed to pro-inflammatory LPS, promoting attenuation of inflammatory action through TNF tolerance mechanisms.
- Normalizes respiratory system function through gene expression regulation.
- Restores and maintains lung alveolar tissues and bronchial mucous membranes.
- May modulate mucosal function in chronic obstructive pulmonary disease.
- Inhibits TNF production in monocytes, reducing inflammatory responses.
- Supports SOD and antioxidant gene expression.
- Researched as potential agent that may slow cell aging.
- Modulates c-Fos and proliferative gene activity.
Research notes
- Generally well-tolerated
- Minimal side effects reported
- Allergic reactions
- Unusual respiratory symptoms
- Active respiratory emergencies (seek medical care)
- Known hypersensitivity
- Pregnancy or breastfeeding
FAQs
Can Chonluten be taken orally or must it be injected?
Chonluten is available in multiple forms including oral capsules, sublingual, and injectable routes. As a short tripeptide, it has favorable absorption when taken orally (10-20mg daily) or sublingually for enhanced absorption. Most commonly used as a 10-20 day oral cycle, though injectable forms bypass GI metabolism for direct delivery.
How often should Chonluten cycles be repeated?
Standard protocol involves 10-20 day cycles repeated 2-3 times per year with breaks in between. After completing a cycle, effects persist for weeks due to epigenetic changes in gene expression, so spacing cycles allows the body to maintain benefits while avoiding habituation.
Does Chonluten help with chronic respiratory issues like COPD?
Research shows Chonluten has moderate effectiveness for COPD support through TNF inhibition and restoration of lung alveolar tissues. It normalizes respiratory function through gene expression regulation, though it works best as a preventative and maintenance therapy rather than an acute treatment for active respiratory emergencies.
What makes Chonluten different from other immune-supporting peptides?
Chonluten is specifically derived from bronchial lung tissue and targets the respiratory system primarily, unlike broad immune peptides. It regulates genes like c-Fos, HSP70, SOD, and TNF-alpha to reduce inflammatory responses and support lung tissue health, making it unique for respiratory-specific immune modulation.